Semaglutide reduced brain damage and neurological deficits in a rat stroke model by shifting microglia from a pro-inflammatory (M1) to an anti-inflammatory (M2) state and inhibiting NF-κB signaling.
M1 → M2 microglial shiftSemaglutide switched brain immune cells from neurotoxic (M1) to neuroprotective (M2) phenotype, reducing inflammation and brain damage after stroke
What the researchers found
In a rat transient middle cerebral artery occlusion (tMCAO) stroke model, semaglutide treatment produced multiple neuroprotective effects:
- Decreased neurological deficit scores on days 1, 3, and 7 post-intervention
- Reduced cerebral infarct volume (measured by TTC staining)
- Decreased CD68 expression (marker of pro-inflammatory M1 microglial activation)
- Decreased TNF-α levels (pro-inflammatory cytokine)
- Increased CD206 expression (marker of anti-inflammatory M2 microglial activation)
- Increased TGF-β levels (anti-inflammatory mediator)
- Reduced P65 levels in the NF-κB signaling cascade
The mechanism involves semaglutide promoting microglial phenotype transformation from M1 (neurotoxic) to M2 (neuroprotective) while inhibiting NF-κB-driven inflammation.
Why it matters
Stroke is the second leading cause of death worldwide, and reperfusion injury worsens outcomes even after successful blood flow restoration. There are currently no approved drugs to specifically prevent this secondary damage. If semaglutide — a drug already prescribed to millions — can protect the brain during stroke recovery, it could be rapidly repurposed for this new indication. The finding also adds to growing evidence that GLP-1 drugs have neuroprotective properties beyond their metabolic effects.
How the study worked
A transient middle cerebral artery occlusion (tMCAO) rat model was established to simulate ischemic stroke with reperfusion. Semaglutide was administered as treatment. Neurological deficits were assessed using modified neurological severity scores on days 1, 3, and 7. Infarct volume was quantified by 2,3,5-triphenyltetrazolium chloride (TTC) staining. Microglial phenotypes and inflammatory markers were assessed using immunohistochemistry and immunoblotting (Western blot) for CD68 (M1), CD206 (M2), TNF-α, TGF-β, and NF-κB p65.
What this study cannot tell us
This is a rat model of stroke that may not fully replicate human cerebrovascular disease. The tMCAO model produces a standardized ischemic injury, but human strokes vary enormously in location, size, and timing. The semaglutide dose and dosing schedule are not detailed in the abstract. Sample sizes per group are not specified. The 7-day observation period is short for assessing long-term neurological recovery. The M1/M2 microglial polarization framework is an oversimplification of complex microglial biology. No behavioral or cognitive assessments beyond basic neurological scoring are described.
How to read the evidence
This is a preclinical animal study using an established rat stroke model with multiple mechanistic endpoints (neurological scoring, infarct volume, immunohistochemistry, Western blot). The evidence is consistent and mechanistically coherent but has not been validated in human stroke patients.
When this study was published
Published in 2024, this study adds to the rapidly growing evidence for GLP-1 agonist neuroprotection, coinciding with ongoing clinical trials of semaglutide for Alzheimer's disease.
The bigger picture
GLP-1 receptor agonists are increasingly recognized as having effects far beyond blood sugar and weight control. Neuroprotection is one of the most exciting frontiers — GLP-1 receptors are expressed in the brain, and multiple studies have shown benefits in models of Alzheimer's disease, Parkinson's disease, and now stroke. Semaglutide is already being tested in clinical trials for Alzheimer's (the EVOKE and EVOKE+ trials). This stroke study adds another neurodegenerative/neuroinflammatory condition where GLP-1 agonists might help, expanding the therapeutic horizon for these peptide drugs.
Questions still open
- Could semaglutide or other GLP-1 agonists be given to stroke patients during or immediately after reperfusion therapy to reduce secondary brain damage?
- Are diabetic stroke patients already taking GLP-1 agonists protected from worse reperfusion injury compared to those on other diabetes medications?
- Does the neuroprotective effect of semaglutide in stroke share the same mechanisms as its potential benefits in Alzheimer's and Parkinson's disease?
Common questions
How does semaglutide protect the brain during a stroke?
Could people already taking Ozempic for diabetes or weight loss get stroke protection?
Read the original research
Effects and mechanisms of long-acting glucagon-like peptide-1 receptor agonist semaglutide on microglia phenotypic transformation and neuroinflammation after cerebral ischemia/reperfusion in rats.
Brain circulation, 10(4), 354-365
Citation
Mi, Rulin; Cheng, Huifeng; Chen, Rui; Bai, Bo; Li, An; Gao, Fankai; Xue, Guofang. (2024). Effects and mechanisms of long-acting glucagon-like peptide-1 receptor agonist semaglutide on microglia phenotypic transformation and neuroinflammation after cerebral ischemia/reperfusion in rats.. Brain circulation, 10(4), 354-365. https://doi.org/10.4103/bc.bc_38_24